Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D Status in Adolescence: Measurement and Functional Meaning: Full Evidence Review

Previous related pageVitamin D Status in Adolescence: Measurement and Functional Meaning: Study SummaryNext related pageVitamin D Status in Adolescence: Measurement and Functional Meaning: Study Summary
Study at a glance

What was studied?

Studies of five separate groups help explain vitamin D blood results during adolescence. They included repeated measurements, supplement trials and an observational study of calcium absorption. Some participants were younger children.

What was found?

An early-adolescent result did not clearly predict values many years later in one group followed over time. Supplements could raise the measured vitamin D marker without clear improvements in calcium absorption or other measured functions.

What does it mean?

A result describes a particular measurement at a particular time. It does not directly measure every tissue response or reliably represent all later years.

What are the limits?

The studies differed in age, previous treatment and starting status. They did not establish one universal adolescent target, a testing schedule or the best laboratory method.

Read the full article below ↓

A blood vitamin D result describes a particular measurement at a particular time. In adolescence, interpreting it also requires attention to growth stage, previous treatment, the substance measured and the outcome of interest. This review compares five independent cohorts to ask how well a result represents later years, whether a rise demonstrates improved function, and what can reasonably be inferred from relationships with hormones and calcium absorption. For the shorter account, read Vitamin D Status in Adolescence: Measurement and Functional Meaning: Study Summary.

Begin with the measurement, not the label

Most studies here measured 25-hydroxyvitamin D, abbreviated 25(OH)D, as their circulating status marker. Some also measured 1,25-dihydroxyvitamin D, the active hormone. These are different substances. Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D explains that distinction. A statement about “vitamin D levels” becomes ambiguous if it moves between them without saying so, particularly when the scientific question concerns a relationship between precursor availability and hormonal regulation.

A concentration, a category and a functional outcome are also different things. The concentration is the reported laboratory quantity. A category such as deficient or sufficient applies a chosen threshold. A functional outcome may be an absorption measurement, bone change or clinical event. Moving from one to another requires evidence. A threshold is not itself proof that every outcome changes sharply at that point.

What Vitamin D Levels Represent provides the broader biomarker context. For adolescents, the additional challenge is that age, developmental stage and exposure can change during follow-up. A useful result need not be a permanent personal characteristic. Equally, the possibility of change does not make the result meaningless. The interpretation should match the time period and physiological question the measurement can actually address.

Does an early-adolescent result represent later adolescence?

Poopedi and colleagues followed a Johannesburg cohort with repeated 25(OH)D measurements between ages 11 and 20. Ninety-nine participants from a larger cohort met the repeated-sample criteria, and 76 had final-age data. Adjacent periods showed correlations, but early values did not clearly correlate with later-adolescent values. Each person’s samples were tested together, reducing variation between assay runs.

This is direct evidence about temporal tracking, not proof of a disease consequence or analytical failure. Selection, attrition, locality, seasonal timing and changing exposures limit generalisation. A single measurement should not automatically stand for a decade of exposure, but the study does not show that it is unsuitable for describing the current sampled state or establish a repeat-testing interval. Other reports from this cohort are not independent replications.

The distinction between ranking and concentration helps interpret such findings. Ranking asks whether someone remains relatively high or low compared with others. Absolute change asks how far their value moves. These questions can give different answers. A group can retain some relative ordering while individual values change; alternatively, a group average can remain similar while individuals exchange positions. Neither pattern can be understood from a single average alone.

Vitamin D Status Over Time: Fluctuation, Stability and Single-Measurement Limits: Evidence Synthesis develops these timescale distinctions using other populations. Its adult evidence cannot determine the adolescent pattern, but it helps explain why a measurement may answer one question well and another poorly. Estimating a long-term exposure from one sample requires assumptions about persistence. Testing those assumptions is different from challenging whether the laboratory measured that sample accurately.

A supplement response is not a complete functional assessment

Lewis and colleagues’ GAPI trial randomized 323 early-pubertal children aged 9 to 13 to placebo or different D3 doses for 12 winter weeks. Blood 25(OH)D increased with dose, while measured fractional calcium absorption and PTH did not show corresponding treatment improvement. Most participants were not severely deficient, and adherence was limited. The absorption assessment used an oral stable-isotope prediction method.

For measurement interpretation, this provides a concrete example of divergence between a blood-marker response and a measured function. It does not demonstrate that absorption is independent of vitamin D in all circumstances. Nor does it establish an ideal concentration. Companion analyses use the same GAPI participants and cannot be counted as independent trials simply because they report different outcomes.

Vitamin D and Calcium Physiology supplies the underlying mineral-regulation context. When a trial measures both a marker and a function, each result should be stated separately. The marker change confirms something about the intervention’s biochemical effect. The functional comparison determines whether the additional outcome was demonstrated. Substituting the first for the second makes a stronger claim than the experiment supports.

This principle also limits interpretation of a null result. If the functional measurement is imprecise, the study is short or participants begin in a different state from the reader’s population of interest, uncertainty remains. The appropriate wording is that an effect was not established under those conditions. It is not that the function is irrelevant or that every possible effect has been disproved.

Can PTH identify one optimal adolescent target?

Rajakumar and colleagues randomized 157 Pittsburgh-area children aged 8 to 14 to D3 or placebo for six months. Mean 25(OH)D rose with supplementation, without clear overall improvement in PTH or bone-turnover outcomes. A statistically supported PTH plateau was not identified, but relatively few high 25(OH)D observations limited that test. About 39% were prepubertal, so this was mixed childhood and early-adolescent evidence.

The study used mass spectrometry that excluded the 3-epimer, a closely related molecule with a different spatial arrangement, from its reported 25(OH)D value. Samples were nonfasting and collected throughout the day. Within-child hormone associations were weaker than between-child associations and attenuated after adjustment. The trial did not measure bone density or calcium absorption. It therefore adds important interpretive limits without establishing a universal target or a race-specific dosing rule.

A plateau would be a feature of a measured relationship, not automatically the concentration that optimises every outcome. Conversely, failure to detect a plateau cannot establish that no plateau exists outside the observed range. The range of the data and the purpose of the endpoint both matter. Choosing a target from a fitted curve requires more justification than identifying a visually suggestive bend.

Between-person and within-person comparisons answer different questions. A relationship across individuals may reflect differences that remain relatively stable between them. It does not guarantee that changing one person’s concentration will reproduce the same association. Repeated measurements and randomized comparisons can test parts of that inference, but they do not eliminate every measurement or design limitation.

Previous treatment and baseline status affect response interpretation

Putman’s Boston trial compared two active D3 doses in 56 adolescents aged 11 to 19; 53 completed 11 weeks. Participants began above the study’s sufficiency threshold, and 13 had received recent deficiency treatment without washout. There were no clear between-dose differences in 25(OH)D change, PTH, bone-turnover markers, fasting glucose or insulin. There was no untreated placebo group.

Consequently, stable values cannot show what would have happened without supplementation. Small numbers and pretreatment limit precision and interpretation, and the null comparisons do not establish equivalence. This independent cohort is useful because it illustrates how the starting state and comparator alter the meaning of a response. It cannot provide a treatment rule for deficient or obese adolescents.

The same final concentration can arise after different histories. A value measured after recent treatment is not equivalent evidence about an untreated trajectory. Likewise, “no change” can mean stability relative to baseline while a suitable untreated comparator might have changed differently. Interpretation requires the relevant history and comparison; the number alone cannot supply them.

Vitamin D and Metabolism helps distinguish a metabolic system from the particular markers measured in a short trial. Fasting glucose and insulin are not every aspect of metabolic function. A blood vitamin D result cannot be promoted into a general metabolic-health score simply because those systems are biologically connected. The claims must remain attached to the endpoints actually studied.

Precursor, active hormone and absorption can differ

Abrams and colleagues analysed vitamin D metabolites, PTH and dual-isotope calcium absorption in 93 Houston adolescents at the end of a prebiotic trial. Vitamin D exposure was not randomized. Absorption was associated with PTH and active 1,25-dihydroxyvitamin D, but not with 25(OH)D overall. Severe deficiency was scarcely represented, and several analyses depended on selected cutoffs or adjustment choices.

The findings support distinguishing analytes and functions; they do not prove a complete compensatory mechanism or validate a diagnostic cutoff. Reports about the prebiotic intervention or genotype in the same participants describe overlapping evidence. This is a fifth independent cohort for the present review, with a different assigned role from the tracking and supplementation studies.

Vitamin D and Bone provides the skeletal context, but neither a hormone association nor an absorption measurement is a direct fracture outcome. The distinction is not a technicality. Each measurement captures a different part of the question. Preserving that distinction makes it possible to explain why an apparently reassuring value in one measurement does not answer every question about another tissue or function.

What the five cohorts contribute

The doses below describe research exposures, not personal recommendations. IU means international units. P values describe statistical evidence under a study model; they do not measure effect size or establish clinical importance.

Study and designMeasured resultInterpretation limits
Poopedi, 2015: Johannesburg adolescent cohort99 selected participants had repeated measurements from ages 11 to 20; 76 had age-20 results. Of these 76, 35 (46%) changed by more than 20 nmol/L between ages 11 and 20. Early measurements did not clearly track late-adolescent values.Selected subset, missing visits and one setting. Long-term change does not invalidate the original measurement or establish a repeat-testing interval.
Rajakumar, 2015: 157 children aged 8 to 14; six-month trialD3 1,000 IU/day versus placebo. Mean 25(OH)D was 19.8 versus 18.8 ng/mL initially and 26.7 versus 22.4 at six months (adjusted between-group P = 0.003). Overall PTH and bone-turnover effects were not clearly beneficial.133 had six-month 25(OH)D results; about 39% were prepubertal. Sparse high values, daytime nonfasting samples and no absorption or bone-density endpoint limit target inference.
Lewis, 2013: 323 early-pubertal children; 12-week trialFive nominal daily doses from placebo to 4,000 IU D3 produced a clear 25(OH)D dose response. Model-derived asymptotic gains (estimated approach to a plateau) were −10 versus +76 nmol/L at the extremes; calcium absorption did not clearly improve.Mostly above 50 nmol/L initially. A biomarker increase and a functional benefit are different outcomes; assay, adherence and actual dose differences matter.
Putman, 2013: 56 adolescents; 11-week active-dose comparisonD3 200 versus 1,000 IU/day; 53 completed. Mean 25(OH)D changes were 0.8 versus 1.0 ng/mL in Table 2 (P = 0.87). PTH change also did not clearly differ (P = 0.35).No untreated arm; previous treatment differed between groups. The table values are used because prose rounding differs. This is not an equivalence finding.
Abrams, 2005: 93 young adolescents; observational analysisAdjusted calcium absorption was not clearly associated with 25(OH)D (P = 0.77), but was positively associated with active hormone (P = 0.048) and PTH (P = 0.007).Precursor, active hormone and regulatory hormones are different measurements. Most participants were not severely deficient; associations are not treatment effects.

Three of these cohorts also inform the companion adolescent-growth review. Their reuse is deliberate: there they explain mineral and endocrine physiology; here they explain measurement interpretation. Reusing a cohort for another question does not create a new independent study. The five underlying cohorts in this review remain five, and multiple papers from any one cohort do not multiply that count.

Functional Vitamin D Status provides the wider distinction between circulating availability and biological response. The present evidence makes that distinction concrete in adolescent populations, while also showing where evidence is indirect. Mixed-age results are labelled, and neither adult repeat-measure studies nor cell experiments are substituted for adolescent clinical observations.

Measurement considerations without inventing a testing rule

The studies used different assays and sampled under different conditions. Those details should accompany interpretation, but these papers were not a head-to-head analytical validation of laboratory platforms. They cannot rank all tests by accuracy. Biological Noise in Vitamin D Testing addresses the broader distinction between biological and analytical variation; this review does not estimate either source of variation from data that did not separate them.

Units must also remain explicit. Comparing bare numbers without their units or the measured analyte can create a disagreement that is only a reporting difference. Historical threshold categories should be identified as the authors’ definitions. Neither the use of a familiar label nor agreement between two papers makes that label a universally validated boundary for every adolescent outcome.

For a research claim, the practical questions are whether the sampling time matches the intended exposure period, whether previous treatment is known, whether developmental stage is described, and whether the endpoint is a marker or a function. These are principles of interpretation, not instructions to order particular tests or repeat them at a fixed interval. The assessed studies do not establish such a schedule.

Source access and supported conclusion

Principal texts, material tables and captions were assessed for all five cohorts. No unseen-figure estimate is used. Rajakumar’s separate supplementary tables were unavailable, so supplement-only coefficients and detailed sunlight subgroup claims are excluded. This selected review does not establish a universal adolescent target, laboratory-platform superiority or a personal supplement dose.

An adolescent 25(OH)D result can be informative without representing every later year or every physiological function. Repeated observations test persistence; intervention studies test response; additional functional measurements test whether a biochemical change has the expected consequence. The evidence is most useful when those questions remain separate and the conclusion states exactly which one the study answered.

Scientific references

Does vitamin D status track through adolescence?. Poopedi MA et al. Am J Clin Nutr. 2015;102:1025 to 1029.

Effect of Vitamin D3 Supplementation in Black and in White Children: A Randomized, Placebo-Controlled Trial. Rajakumar K et al. JCEM. 2015;100:3183 to 3192.

A Randomized Trial of Vitamin D3 Supplementation in Children: Dose-Response Effects on Vitamin D Metabolites and Calcium Absorption. Lewis RD et al. JCEM. 2013;98:4816 to 4825.

A randomized clinical trial of vitamin D supplementation in healthy adolescents. Putman MS et al. J Adolesc Health. 2013;52:592 to 598.

Relationships among Vitamin D Levels, Parathyroid Hormone, and Calcium Absorption in Young Adolescents. Abrams SA et al. JCEM. 2005;90:5576 to 5581.

Related reading

Original sources

Source

Does vitamin D status track through adolescence?1

The percentage of adolescents whose 25(OH)D concentration changed by >20 nmol/L from year 11 was calculated for all age groups: 12% of the cohort had a change of >20 nmol/L at 13 y of age compared with 46% at 20 y of age.

Publication details

Does vitamin D status track through adolescence?. Poopedi MA et al. Am J Clin Nutr. 2015;102:1025 to 1029.

Read more →